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Abstract 
 
In this article, we reflect on the possibilities that PrEP (HIV pre-exposure prophylaxis) 
raises for HIV specialist clinicians. Often neglected, yet a direct participant at the 
intersection of a complex tension within public health debates on how to reduce HIV 
transmission and the sexual sociability of individuals, we reflect on current thinking of 
health practitioners involved in the day-to-day practice of prescribing PrEP. Drawing 
on interviews with practitioners in the context of UK sexual health and HIV specialist 
medicine, while bearing in mind neoliberal critiques and process studies of medical 
science, we propose that PrEP invites the possibility for reconstituting approaches to 
sex and risk.   
 
Key Words: HIV PrEP, clinical medicine, sex and drugs, neoliberalism, process 
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PrEP (HIV pre-exposure prophylaxis) and its possibilities for clinical 
practice   
  
Although the prospect of a daily pill, PrEP (HIV pre-exposure prophylaxis) to protect 
against HIV infection might have been expected to receive unqualified support, it has 
raised and, in some ways, reignited a longstanding debate on prevention in relation to 
the sexual cultures of gay men, men who have sex with men (MSM) and transpeople. 
Underpinning much of the debate is a connection that has been made between the 
introduction of treatments and a decline in condom use (Ostrow et al., 2002; Stolte et 
al., 2004). While the availability of PrEP is proposed to address this decline, some see 
it as having the potential to exacerbate the decline amongst others who are not on PrEP 
or taking HIV treatment (which can also prevent HIV transmission), with the 
paradoxical consequence of not less but sustained or, even, increased HIV infection 
rates. Psychological phrases such as ‘risk disinhibition’ or ‘risk compensation’ drawn 
from a theory that ‘predicts that people are more likely to participate in risky practices 
with the advent of biomedical disease-prevention strategies’ are often used to explain 
the above concern with PrEP (Grant et al., 2014: 820; see also Cassell et al., 2006; 
Underhill, 2013; Holt and Murphy, 2017; Blumenthal and Haubrich, 2014).  
 
However, while there may be some ground for concern and including a rise also in 
other STIs, insofar as the theory is underpinned by the neoliberal presupposition that 
individuals should and can be responsible for their health but, in practice, are unlikely 
to be so (Greco, 2017: 112), it can be argued to eclipse much of what has contributed 
to existing modes of HIV prevention. The embracing of notions of ‘self’ and 
‘community responsibility’ have been at the forefront of highly successful prevention 
efforts by gay self-identified men and MSM (Kippax and Race, 2003; Watney, 1990). 
Indeed, it would seem that the anticipation of ‘risk disinhibition’ or ‘risk compensation’ 
piggybacks on how condom use has become a norm for determining responsible 
conduct (Adam, 2005; Thomann, 2018).  
 
Not surprisingly, a series of arguments have been mounted to broaden the response to 
PrEP and, specifically, to redress what amounts to a neglect of the complex possibilities 
 4 
posed by PrEP in relation to sex, HIV and other STIs. Much of the focus on the decline 
in condom use tends to overlook substantive social research that shows inventive 
strategies may be employed by gay men and MSM to avoid HIV exposure (Kippax and 
Race, 2003; Parsons et al., 2005; Rosengarten, 2009) while conflating the avoidance of 
STIs with condom use1. It is also neglects what Holt (2015:436) discusses of the 
honesty that gay men have shown in providing detailed articulation of the limitations 
of their current practices including, in some cases, acknowledgment that they are likely 
to continue having sex without condoms. On the basis of Holt’s (2015:436) 
observations, it would seem there may be constructive work to be developed with the 
evident degrees and modes of trust that are involved in sexual practices as well as those 
that happen in relation to research and, more particularly, in clinical encounters where 
STIs may be addressed. 
 
In concert with efforts to broaden the approach to PrEP (Michael and Rosengarten, 
2013; Race, 2015; Thomann, 2018), Judith Auerbach and Trevor Hoppe (2012), focus 
on what they see as an overly determined and moral focus on risk. As they phrase this, 
‘the potential for PrEP to confer a new level of agency, control and pleasure in sexual 
relations, in combination with the fears of ‘‘risk compensation,’’’ does little more than 
fuel ‘a new sexual moralism, particularly within gay communities’ (2015:2). These 
authors acknowledge that responsibility for the transmission of HIV may well intensify 
the shift from a community and couple-focused response seen with the introduction of 
antiretroviral treatments, placing a more individualized onus on those who are HIV-
negative. That is to say, it may have consequences for HIV transmission. But they also 
suggest that it may have other consequences, and that by reducing the fear of HIV 
and/or the need for condoms that can mediate sexual pleasure, new styles of negotiation 
may emerge. Indeed, as Newman et al (2018) found in their research with policy and 
clinical stakeholders in PrEP’s futurity, not only is there an imagining of whom PrEP 
will be suited for, but a diversity in this thinking that cautions against deciding in 
advance who and how these populations may emerge and thus, we add, may continue 
to change.   
 
Nevertheless, although it is apparent that there is a need for new thinking on HIV 
prevention and underscored by the complex challenges and possibilities raised in 
response to PrEP and in relation to gay men and MSM, as is the focus above, it is 
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conceived largely in the abstract. With some exceptions (Arnold et al., 2012; Koester 
et al., 2017; Newman et al., 2018; Race, 2015) most research studies have been 
conducted on the acceptability, awareness of, or barriers to PrEP uptake, prior to any 
actual or substantive experience of its use by sexual actors at the centre of the debate 
or with those involved in prescribing it (see for example Frankis et al., 2016; Witzel et 
al., 2018; Young et al., 2014). Bearing in mind the contours of the debate and the need 
to extend the repertoire of factors that may affect what PrEP becomes for its users, in 
this article we focus on what some health practitioners have made of it in-situ.   
   
In what follows, we reflect on findings from a small interview-based study that we 
undertook with health practitioners actively involved in prescribing PrEP.2 Our 
intention in conducting the study and what may be considered a small number of 
participants (N = 7) was to learn from the direct experiences of practitioners actively 
involved in negotiating the sorts of concerns and counter arguments set out above. As 
may be evident from the extracts included below, our open-ended interview questions 
reflected what has been raised about the risks due to the absence of condoms, including 
an increase in STIs as well as HIV and, also, in relation to the practice of what is 
referred to in the United Kingdom as ‘chemsex’ or ‘party and play’ elsewhere and 
involves recreational drugs3 in situations of a number of sexual partners (Bourne et al., 
2015; Gilbart et al., 2013; McCall et al., 2015)4. To be clear, our aim was not to generate 
findings that would be assumed representative of other health practitioner views. Nor 
was it done on the assumption that the views we gathered will necessarily remain stable. 
Indeed, we would anticipate that as new issues and practicalities emerge in what we 
have already noted above as a dynamic epidemic of changing sexual patterns and 
medical developments, so too may practices with PrEP alter amongst our health 
practitioners as well as may be said of PrEP users.  
 
Our interviewees5 – six doctors and one sexual health advisor6 – were selected on the 
basis that they were working in London-based sexual health clinics involved a trial 
called IMPACT,7 which aims to assess the feasibility of providing PrEP through 
England’s publicly funded National Health Service (NHS)8. Outside the trial, PrEP was 
only available at a cost through private clinics or by purchasing generic versions. 
Although we anticipated that our research participants would be influenced by aspects 
of the current debate on PrEP, we remained curious about what they made of the various 
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arguments for and against PrEP given their direct ‘at the coal-face’ determinations 
when prescribing PrEP.  Although some interviewees reflected on their engagements 
with PrEP beyond this particular trial, for the most part, interviewees focused on their 
experiences of prescribing PrEP in the context of IMPACT, which is predominantly 
populated by gay and MSM and, as such, consistent with HIV prevalence in the UK.  
 
Beyond HIV Prevention 
Given the pervasiveness of the neoliberal tone of ‘risk compensation’ or ‘risk 
disinhibition’ that constitute individuals as responsible for their health and thus risk, 
one might assume that healthcare professionals would be likely to stress the importance 
of personal responsibility and rational choice in sexual decision-making. Indeed, in an 
article about drug adherence, Maskovsky (2005) notes that when doing research in a 
clinic in the late 1990’s he would often hear clinicians comment that a patient had failed 
their drugs by taking them incorrectly, rather than attending to the difficulties drug 
regimens might pose to successful adherence. Thus, while we may have expected to 
find recourse to neoliberal evaluations of patients by our interviewees, what we offer 
here suggests that the space of the clinic can be practically attuned to the complex 
dynamics of sex, HIV and, notwithstanding, recreational drug use.     
 
Resonant across our interviewees, here anonymized with the use of fictitious names, is 
how PrEP has been incorporated into the already established processes and concerns of 
the sexual health clinic. This approach occurred early on in an initial sexual risk 
assessment with patients, while taking account of a number of co-affecting factors 
pertinent to the situated risk practices and negotiations of the individual patient. For 
Vida, navigating these factors was made possible by a standardized protocol for gaining 
insight into multiple issues:   
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‘This is not just about PrEP, this is about other stuff so for example 
in this clinic we don't just talk about HIV prevention. You do the 
questionnaire with the drug use disorders identification toolkit, it’s a 
bit like the alcohol audit, where you do a score and a score with 6 for 
men warrants further exploration. We do alcohol audit score, so a 
score of 8 or more will warrant some sort of discussion. And we do 
a PHQ9 and GAD7 which is the depression and anxiety 
questionnaire. So they fill all of that in prior to seeing the clinician 
so you kind of see [if] you've got an anxious depressive, that's 
somebody doing loads of drugs, who wants PrEP, yeah PrEP [would 
then be] a minority of the consultation [and] we [would] focus on the 
other stuff. And for people who just need PrEP they just need PrEP, 
a lot of people are just really well and just don't want to get HIV and 
that's fine.’  Vida 
 
Insofar as the questionnaire referred to above could be argued as a participant in shaping 
the clinical consultation (Michael, 2004; Race, 2012) and according to a calculative 
and, thus, highly normative mode of assessment, it is not surprising that a public health 
concern for risk – whether HIV, drug use or depression – prevails and, in some respects, 
is safeguarded by standardised protocols. However, this did not mean that the risks 
presumed to be posed in relation to matters of the individual patient were reduced to 
correcting a patient’s practices. While on the one hand, the protocol functioned to set 
the ground for the clinical encounter, on the other, it was also seen as limited as a 
consequence of doing so. For Cooper, cited below, the standardised approach reliant 
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on a scale of risk was considered inadequate to the task of responding to the dynamic 
constraints of a patient’s sex life.   
 
‘there are various routes into the clinic but all of them would involve 
a sexual risk assessment, and that may be self-reported sexual 
behaviour or it may be clinician collected. So in our walk in service 
we actually do a lot of computer assisted self-interview stuff that 
people type it all onto a screen. Invariably it’s not granular enough 
so most people would then interrogate the patient and understand a 
little bit more about their sexual behaviours, where they meet their 
partners, total number of partners, use of barrier methods or 
contraception [in a] heterosexual context, and then in a more 
traditional face to face clinical consultation that’s obviously part and 
parcel of routine clinical practice in terms of a sexual history.’ 
Cooper 
 
When asked about whether the kinds of initial discussions they had with HIV positive 
patients and HIV negative patients looking to access PrEP differed, all interviewees 
answered with a very explicit ‘no’. William, cited immediately below, explained that 
they would be interested all their patient’s sexual practice and other contributing factors 
to it,   
 
‘I like to think my advice wouldn’t be different in the sense that I 
would assess their sexual history, how many partners they had in the 
past three months, and the types of sex they are having, where they 
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are having sex, is it anonymously and so on, so is it through Grindr 
[online hookup application], and just try to have a chat with them 
about why they are accessing these [sites], why they are choosing 
their sex in … particular settings, and if there was any underlying 
deeper reasons behind it, for example are they having sex in saunas 
because they feel like they cannot openly go out and meet people, 
look for people.’ William 
 
Nevertheless, this did not preclude the fact that PrEP created opportunities to broaden 
the doctor-patient relationship when talking with HIV negative patients. Importantly, 
and not unlike a more longstanding practice, this involved careful negotiation of public 
health determinations of wrongful behaviours such as ‘chemsex’ and ‘risk 
compensation.’ But with the aid of PrEP, it became possible to cultivate what could be 
argued as a practicable response to averting certain risks. As Vida described PrEP, it 
provided the opportunity to remove the risk of HIV transmission while dealing with 
other pressing concerns of the field such as chemsex:  
 
‘Particularly those having chemsex where sometimes it’s HIV that 
brings them in for PEP [post exposure prophylaxis] or stops them 
taking the extra bit of drug or whatever it is, … and then for them I 
just say, “Well listen, you just need to work out what you’re doing 
about your chemsex issue whilst not getting HIV.” So we just take 
HIV out of the equation [by using PrEP] and deal with risk 
[associated with chemsex, which] is bad enough without HIV, as 
drug induced psychosis is pretty bad … it can be permanent if you 
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keep carrying on repeating, [you’ll] need drugs, medication forever 
like [you would if you had] HIV. So, you’ve got to just think about 
it as a separate entity and you might as well get to go through your 
journey with all of that whilst not getting HIV’ Vida 
 
In some respects, the above can be viewed as complimentary to what Holt (2015) 
proposes of the trust by gay and MSM in disclosing their sexual practices and the 
capacity for health practitioners to respond within the clinical encounter. The extract 
also suggests that at the ‘coal face’ of medicine, the distinction between biomedical 
objects and social behaviours can be reworked and in ways that are responsive to this 
trust. Unlike what has been said of a conception of PrEP as if a distinct object with 
fixed capacities and, as has been argued of the manner by which diagnoses and 
technological interventions affect and are affected by users or prescribers (Mol, 2003, 
2008; Race, 2012; Rosengarten, 2009), in practice the actual prescribing of PrEP 
reflected a less science dominated mode of thinking. While it may be that health 
practitioners proceed according a logic that presupposes sex and risk as well as drugs 
are distinct causal entities, their approach was more akin to seeing sexual encounters as 
contingent on mix of ‘practices, procedures, devices, circumstances, and occasions of 
cognition’  (Race, 2012: 333). 
 
Indeed, a more relational conception of what makes for a risk event can be deduced 
from how Vida suggests that a patient’s sexual relations may differ with different 
partners and drugs. That is to say, although PrEP was embedded into a systematic mode 
of assessment constructed according to a standardized assessment of risk, in the day-
to-day realities of patients’ life styles, our practitioners were, to a degree, attuned to the 
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need for a mode of thinking beyond that of a normative protocol. More particularly, for 
Vida, a presumed continuum of risks warranted a response attuned to the contingencies 
of sex in relation to drugs, alcohol, digital hookup technologies as well as what is often 
termed as related psychological wellbeing. 
 
Navigating concern for risk 
Insofar as the prevailing concern with ‘risk compensation’ was familiar to our 
interviewees and in some of the discussion acquired explicit expression, there was the 
added concern that the decline in condom use may lead to the rise of other sexually 
transmitted infections (STIs). For both clinicians and other members of the HIV field, 
including those involved in policy development, the issue of STI transmission has a 
long history that pre-dates its emergence in debate on PrEP (Cairns et al., 2016). 
Nonetheless, while bearing this in mind, what was relevant to our interviewees was 
what they perceived as the current reality: some patients would not be using condoms 
irrespective of the risk of STIs. For this reason, PrEP remained an important prevention 
technology. As William described this reality for some of his patients: 
 
‘it’s interesting when you see people who absolutely are in a way 
committed to a lifestyle without using condoms, they know they are 
at risk, they don’t use condoms, perhaps there’s an element of 
sexualised drug use, chemsex use on top of that, and then they hear 
about PrEP as something that all their friends, their mates are doing, 
and they think well that’s a step I’m willing to take, I’m not willing 
to use condoms, but I’m willing to take a tablet a day to prevent HIV, 
and that’s something that’s acceptable to me’ William 
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In sum, condomless sex was thought as a practice that healthcare professionals may not 
necessarily be able to change, but which PrEP now enabled them to move on from and 
thus to engage more constructively with the constraints at hand. As such, PrEP was 
framed not as resolving the difficulties associated with attempting to navigate patients’ 
condom-use, but rather as offering an opportunity to assuage the potential harms of 
non-condom use. Framed in this way, PrEP enabled practitioners to depart from what 
some otherwise saw as a demand on them to moralise about the need for condoms 
despite what was felt to be the futility of doing so.  
 
This approach did not ignore what has been said of the possibility of an increase in 
STIs, although we wish to stress that the prospect of such is unclear. Without entering 
into the complexities of the concern, our interviewees sought to contend with the issue 
in a manner that would achieve a practicable difference for patients. When asked about 
the risk of STIs, some of our interviewees situated themselves as in a field of 
controversy within which there are ‘STI deniers:’   
 
‘So I think clinicians fall into, this is a bit arbitrary and possibly a bit 
facetious, but fall into two camps, the STI deniers and the STI 
accepters, and clearly we’re going to see an increase in bacterial STIs 
and it’s nonsense to say that we’re not’ Cooper 
 
‘But there are people out there who are STI denialists in the PrEP 
camp and it’s just ridiculous, you get them saying that, but they are 
saying that because they don’t want any barriers to exist to PrEP 
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adoption. But saying that for me doesn’t mean it’s a barrier to PrEP 
adoption, I think we should have both and just deal with the STIs 
more effectively’ Campbell 
 
While accepting that STIs may increase, William posed the possibility that PrEP could 
contribute to a reduction in STIs where regular STI testing formed part of the PrEP 
package. Although some interviewees suggested that the regular monitoring for the 
purposes of the trial may be less frequent in a wider rollout of PrEP, in the context of 
the trial, 
‘the aim is not just to give PrEP on its own but also to give them the 
gold standard advice and to say come back in for your three-monthly 
screenings, it’s the regular testings and picking up of early [STIs] 
before they get transmitted, that will decrease the rates of sexually 
transmitted infections overall’ William 
 
Further, although PrEP is often referred to as if a standalone object and, as mentioned 
earlier presumed to have causal properties irrespective of contingencies affecting what 
might come of it, all our interviewees spoke of PrEP in relation to what they understood 
to be a realistic response to a patients’ needs and did so by framing PrEP and STIs in 
the context of broader historical patterns that have been generated by existing studies. 
As Ghislaine described, 
 
‘Of course, what HIV had done was to make STIs go away, so we 
had very little syphilis and gonorrhea in that period of late 80s and 
early 90s. And then with the effective treatment of HIV and the 
arrival of all the dating apps and chems[ex] in the early part of this 
century things took off again but if you look at the history of STIs 
over the course of, well [it’s been] 101 years now [that] we've been 
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monitoring gonorrhea in this country, you see how it goes up and 
down with time, see how it goes up in the 60s and 70s, it comes down 
with HIV and [that’s] just the natural fluctuations in STIs’ Ghislaine 
 
In sum, although an increase in STIs was considered a possibility, there was an 
acknowledgement of the ways in which technologies – PrEP, STI testing, chemsex, 
dating apps – participate in patterns of changing sexual practice. In order to think this, 
all but one of our interviewees drew on the history of the contraceptive pill, either in 
terms of its introduction or the ways by which women have utilized the pill to navigate 
sexual practice and the risk of pregnancy. Campbell described this in terms of the fear 
some patients express that PrEP will lead them to dispense with condoms altogether: 
 
‘you meet women who won’t go on the pill because they are worried 
that it will stop them from being sensible about using condoms, and 
then they come in for emergency contraception, because they run out 
of condoms or they are not sensible about condoms because passion 
is passion. So the reality is we need to get past that conversation, it’s 
not ‘either/or’ it’s ‘and.’ So, we say to the woman “go on the pill 
because it’s nice to have belt and braces and if the condom breaks 
you don’t have to come in rushing in for emergency contraception,” 
or maybe not the pill, maybe something long acting and reversible 
like the IUD or the IUS or the implant. But for me it’s the same 
conversation with sexually active gay men, it’s let’s talk about 
prevention, let’s talk about making sure that it doesn’t commit you to 
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have lots of unprotected sex, it just protects you should you need it’ 
Campbell 
 
The quote above from Campbell is suggestive of an attempt to respond not only to risk, 
but also to what patients might think of as the potential outcomes of PrEP use for 
themselves, their own concerns for ‘risk compensation’. In attempting to account for 
complexity, Campbell echoes what can be argued as a neoliberal framing that is tinged 
with a putative moralism – condom non-use is a failure to be ‘sensible’ – but, the same 
time, recasting it more practicably. Indeed, it was interesting to us that in the space of 
clinic it was necessary to move beyond a neoliberal evaluation and do so by reference 
to ‘passion’.   
 
Again by making reference to the contraceptive pill, Vida spoke of the potential 
consequences of ‘risk compensation’ as being much more complex than a simple cause 
and effect and demanding a pragmatic approach for a wanted difference:   
 
‘If we look at what happened to the oral contraceptive pill of the 60’s 
gonorrhoea went up, so I think we will see a bit of that, and I think 
that’s fine, just test and treat more. But then we are now in an era 
where we can diagnose quicker, treat quicker, and therefore less 
people get infected. So we may not see the big surge that we saw in 
the 60s with the oral contraceptive pill introduction because we have 
got new technologies, better technologies, hopefully better access to 
testing, even though treatment facilities are shrinking. So I think we 
shouldn’t be ashamed or be backward in coming forward with risk 
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compensation, of course people are going to have a bit more 
unprotected sex, of course there’s going to be a few more STIs, but 
the question is, is that price worth paying? And I think probably it is, 
because of the benefits.’ Vida  
 
Although Vida echoes William’s suggestion above that STI testing may come to limit 
the potential increase in STI transmission, the acceptance of the possibility, or even 
likelihood, of an increase in STIs in the context of an ostensibly positive outlook on 
PrEP may be surprising. However, what resonated throughout the interviews was an 
often explicit consensus that the answer to the question Vida posed above, ‘is that a 
price worth paying?’ was ‘yes.’ As such, our interviewees were engaged not only in 
considering the various other elements of the HIV event, but also in deciding on which 
issues should be prioritised when accounting for the various outcomes and possibilities 
of PrEP. 
 
Not only were they mindful of what was at stake in terms of transmission – of HIV or 
other STIs – the broader benefits of PrEP were also viewed as being considerably more 
far reaching than HIV prevention alone, as following the previous quote, Vida went on 
to say, 
‘You don’t have a lifelong infection, people can deal with all their 
screwed up issues around sex and pleasure, anxiety and God knows 
what the ramifications are for that, it’s very difficult to measure, 
somebody needs to do lots of qualitative interviews to work out what 
the gains are beyond HIV prevention. So I think to measure it purely 
as an HIV prevention tool is great but there are other potential 
benefits.’ Vida 
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We suggest that Vida’s approach allows for a broad set of issues to be at play with the 
introduction of PrEP.  Just as other interviewees chose to frame PrEP and notions of 
risk compensation according to an extended timeline – one which includes the 
introduction of other biomedical interventions – for Vida, PrEP has the potential for 
outcomes beyond HIV prevention (here, a healthier and happier approach to sex and 
sexuality). Indeed,  it echoes findings from Newman et al’s (2018) study on stakeholder 
perspectives on PrEP. Some participants acknowledged that even those who were not 
deemed to be at high risk of acquiring HIV could benefit from taking it, by way of it 
having the potential to alleviate anxiety around sex (see also Koester et al., 2017). 
Importantly, for our interviewees, specialized knowledge obtained from their patients 
in relation to PrEP afforded an opportunity to cultivate new modes of engaging with 
concerns around sex and sexuality. 
 
Conversations about Sexual Practice  
As suggested above, PrEP was thought of by our interviewees as an opportunity to 
extend the medical arsenal with the aim of better catering to the wants of patients. But 
this was not confined to the use of drugs. Rather, considerable importance was placed 
on how it enabled a conversation to take place between a practitioner and patient that 
was more ‘realist’ about what was felt to matter by the patient. That is to say, our 
interviewees saw themselves as better able to elicit more frank and, thus, practical 
conversations about condom use. Again, echoing and partnering what Holt (2015) 
suggests and here, more particularly in relation to PrEP, the availability of a new 
prevention technology was seen to allow more insight into the ways and extent to which 
condoms were or were not used by patients: 
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‘I think PrEP gives a space for people to tell you what they're really 
doing with condoms, I think before that we were … obviously the 
only thing we had to promote was condoms and it was apparent that 
people were not using them but that was all we had to promote, so 
that was actually demoralising for staff because they knew that they 
were banging on and giving people condoms without any motivation 
of the individual to use them consistently’ Ghislaine 
 
By displacing or complexifying the morality surrounding condom use already present 
within the field (Adam, 2005, 2006; Auerbach and Hoppe, 2015), PrEP was described 
as a gateway to a different style of clinical practice:   
 
‘If I think about years ago trying to facilitate a conversation about 
sexual risk … so it’s all about someone admitting that something that 
they “shouldn’t do,” they are doing. So, they know they should be 
using condoms, they know all of that but they still didn’t use 
condoms. They know they shouldn’t have been using drugs and 
alcohol around sex, and they should have had a clear mind when they 
were talking about sex but they didn’t … But then when PrEP came 
into the conversation it changed the conversation, because you could 
say “actually just tell me, because there’s things I can do to help,” 
and … you allow someone to give them more freedom to be honest I 
felt, and so I felt it really changed the conversations, and I found it 
quite empowering for people … and so you would have those 
conversations and say “look just tell me what happened at that party 
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etc, how many times have you done this in the past week, past month 
etc, do you know that actually there’s a trial that’s available, let’s just 
see if you would be appropriate for it” and then go in that way. And 
then I found, and I think lots of my colleagues would say it as well, 
that people were more honest.’ Alan 
 
While it may not remove morality from sex nor from a more pervasive neoliberal mode 
of responsibility individuals have for their health, the above suggests that PrEP 
introduces a difference to the clinical encounter. The difference is not some ‘thing’ for 
calculable assessment. Rather, it is what enables a move away from what is otherwise 
foreclosed by a reductive notion of responsibility imposed on clinicians as well as 
sexual subjects. For our interviewees it was not just a matter of PrEP assisting in the 
achievement of a more open discussion with patients. As Cooper phrased this, it also 
allowed health practitioners to, themselves, develop a more realistic understanding of 
the sexual lives and desires of their patients, 
 
‘I am trying to say that talking about it shows that you have some 
insight into the sexual lifestyle of the person that you’re talking to. I 
think talking about it also helps you, I guess, demonstrate that we 
understand that sex and sexuality and sexual risk or whatever is 
complex and it’s nuanced in that PrEP may be one arm of it. I think 
possibly the whole condom argument has been a bit one note, and 
whilst condoms are the most effective intervention for all sorts of 
STIs, they have a reek of paternalism about them, and so does 
reducing a number of partners and all this kind of stuff, or sex on 
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drugs or whatever, and I think talking about PrEP helps us sound a 
little bit more, I think pragmatic is the wrong word, but ‘real world 
like’’ Cooper 
 
Insofar as the ability to demonstrate a nuanced, open and non-judgmental 
understanding of the sexual lives of patients is an important factor in HIV healthcare 
(c.f. Palich et al., 2017), there is something of a resonance here with what Maria Puig 
de la Bellacasa (2017:4) has argued for as ‘a politics of care’ that, as she phrases this, 
‘engages much more than a moral stance; it involves affective, ethical, and hands-on 
agencies of practical and material consequence’. Nevertheless, given our interviewees 
were at the front line of approaching health as a static condition, presumed to be 
preserved against a pathological viral or bacterial agent (Canguilhem, 1989) or, indeed, 
a potentially destructive ‘chemsex’ drug (McCall et al., 2015), much of what we have 
included here suggests that PrEP not only warrants a reconfiguring of the prevailing 
conceptions of risk but, more particularly, how it aligns with what can be made possible 
for the cultures it is intended to serve.   
 
Conclusion 
In this paper, we have sought to turn attention to the manner by which health 
practitioners can be shown to engage with what is reflected in current debates on PrEP 
in relation to risk of HIV transmission, others STIs and, also, recreational drugs. By 
extending and entangling PrEP within the various concerns of the clinic, our 
interviewees suggest that PrEP has the possibility of cultivating a mode of medical 
practice that is not only different to a prevailing neoliberalism about what might 
constitute health but, rather, is appreciative of the actualities that may come to 
 21 
constitute a situation of HIV infection. That is to say, rather than responsibilise those 
engaged in sex for a host of potential consequences including but not exclusive to HIV 
infection, it is evident from our material that there exists within the medicalised 
approach opportunities to become more responsive to the situated needs of patients and 
that PrEP can be an enabling factor for doing so.  
 
No doubt, the terrain we have described in this paper and based on a small and highly 
selective focus on specialist sexual health and HIV medicine, will continue to shift. As 
PrEP becomes a more commonplace feature of sexual cultures negotiating HIV risk, its 
possibilities may well change in connection with other familiar but also new comers 
such as new drugs, new infections, new styles of sex and drug use. Indeed, it may need 
to go beyond and may well, in itself, have a bearing on public health framings of risk 
that are, as suggested by notions of ‘risk compensation’ and ‘risk disinhibition’ overly 
attached to moral notions of a self-willed, autonomous but deficient individual.  
 
As we stressed at the outset of this article, the findings of our study are not presented 
here as if representative of the views of other sexual health or HIV practitioners. 
Nonetheless, we suggest that they may have relevance for cultivating prevention 
possibilities beyond debates that fix on PrEP as no more than an object whose worth 
can weighed against risk including but not only that of HIV. Indeed, if as our 
interviewees have suggested to us, the moralising dimensions of debates now 
circulating in relation to what PrEP may do against prevention are not those that 
necessarily need feature in the prescribing or the everyday take up of PrEP, there is 
considerable scope for thinking with encounters in the space of the clinic. To be sure, 
there will always be more to be learnt about the dynamics of sex and medicine for not 
only what PrEP can do, but for what medical practice can become.   
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1 While beyond the scope of this paper, in conversation with colleagues – and supported 
by a small number of studies (Holmes et al., 2004; Warner and Stone, 2007) – questions 
have also been raised regarding the protective capacities of condoms for certain STIs.  
2 Our research was conducted within a Humanities in the European Research Area 
(HERA) funded study ‘Disentangling European HIV/AIDS Policies: Activism, 
Citizenship and Health’ (EUROPACH), designed to consider the ways in which 
histories of HIV are mobilised in current policy and activism.   
3 Usually crystal methamphetamine, mephedrone, GHB (gamma-hydroxybutyrate) or 
GBL (gamma-butyrolactone), sometimes used in combination with Viagra. 
4 Although it should be noted that the picture is likely more complex than much of the 
discussion on chemsex suggests (Race, 2018). 
5 Interviews were conducted by the first author in April and May of 2018. 
6 A distinction is not made between the doctors and the sexual health advisor as we 
found no meaningful qualitative difference between their perspectives. Additionally, 
although social research often employs the use of racial and ethnic identifiers, it was 
not considered appropriate to this project. There was no indication that personal details 
of the professionals interviewed, including their own sexual orientation or gender, was 
present in the discussions of their professional practice.    
7 The PrEP IMPACT Trial is a three-year implementation trial designed to assess the 
need, uptake and duration of use of PrEP and will be used to determine future 
commissioning. Trial sites are sexual health clinics across the country and 10,000 
places on the trial were made available initially, with places being increased to 13,000 
in June 2018 and suggestions that this number may be doubled. 
8 PrEP is available for free on the NHS in Scotland for all who meet the eligibility 
criteria. It is available in Wales through participation in the uncapped PrEPARED Trial; 
and available in Northern Ireland through a (currently uncapped) pilot. 
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